血清囊素C作为超治疗性滴毒素度的危险因素,在患有心力衰竭和慢性病的老年患者中使用
1Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China.
概括
血清囊素C有效地预测心力衰竭和慢性病的老年患者的高迪戈辛水平. 这种生物标志物为监测脆弱人群中药物安全提供了一个敏感的工具.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 老年病的医生 老年病的医生
背景情况:
- 迪戈辛毒性与高度有关,特别是在患有功能障碍的老年患者中.
- 患有心力衰竭 (HF) 和慢性病 (CKD) 的老年患者的风险增加.
- 确定超治疗性狄戈辛水平的可靠生物标志物对于患者的安全至关重要.
研究的目的:
- 为了评估功能生物标志物的预测性表现,用于超治疗性狄戈辛度.
- 为了评估这些生物标志物在老年患者诊断出HF和CKD.
- 确定最敏感的生物标志物来预测狄戈辛毒性风险.
主要方法:
- 对接受狄戈辛治疗的老年患者 (HF和CKD) 的回顾性数据分析.
- 后勤回归用于确定超治疗度的独立风险因素.
- 接收器操作特征 (ROC) 分析,以比较血清肌素,血清囊素C和血液尿素的预测性能.
主要成果:
- 在115名患者中,49名患者具有超治疗性狄戈辛度.
- 估计的淋巴细胞过率,以血清囊素C (eGFRCysC),心率和NYHA类计算为独立的风险因素.
- eGFRCysC切线为41毫升/分钟/1.73米2确定风险;在特定子组 (肥胖,晚期CKD,年龄较大) 中预测性能得到改善.
结论:
- 血清囊素C作为功能生物标志物表现出高度敏感性.
- 它有效地预测了HF和CKD的老年患者的超治疗性狄戈辛度.
- 这一发现支持使用cystatin C进行增强的迪戈辛安全监测.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:17Factors Affecting Renal Clearance: Renal Impairment
95
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:11Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
59
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
59